NasdaqGS - Nasdaq Real Time Price • USD
Tyra Biosciences, Inc. (TYRA)
As of 10:44 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.41 | -0.44 | -1.71 | -2.09 |
| Low Estimate | -0.46 | -0.51 | -1.95 | -2.55 |
| High Estimate | -0.36 | -0.4 | -1.51 | -1.72 |
| Year Ago EPS | -0.31 | -0.49 | -1.62 | -1.71 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.34 | -0.35 | -0.48 | -0.45 |
| EPS Actual | -0.31 | -0.49 | -0.53 | -0.35 |
| Difference | 0.03 | -0.14 | -0.05 | 0.1 |
| Surprise % | 8.80% | -40.00% | -10.40% | 22.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.41 | -0.44 | -1.71 | -2.09 |
| 7 Days Ago | -0.41 | -0.44 | -1.72 | -2.27 |
| 30 Days Ago | -0.44 | -0.47 | -1.89 | -2.4 |
| 60 Days Ago | -0.46 | -0.48 | -1.9 | -2.52 |
| 90 Days Ago | -0.45 | -0.47 | -1.96 | -2.57 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | 1 |
| Up Last 30 Days | 5 | 5 | 5 | 6 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | TYRA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -32.30% | -- | -- | 8.00% |
| Next Qtr. | 10.20% | -- | -- | 12.40% |
| Current Year | -5.60% | -- | -- | 5.60% |
| Next Year | -22.20% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -21.10% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Oppenheimer: Outperform to Outperform | 5/13/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 5/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/10/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 3/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 12/29/2023 |
Related Tickers
AVTE Aerovate Therapeutics, Inc.
20.41
-0.78%
EWTX Edgewise Therapeutics, Inc.
17.88
-1.27%
ELVN Enliven Therapeutics, Inc.
22.76
-1.22%
MLYS Mineralys Therapeutics, Inc.
12.94
-0.46%
ZNTL Zentalis Pharmaceuticals, Inc.
11.89
-1.49%
SYRE Spyre Therapeutics, Inc.
37.16
-1.69%
BCYC Bicycle Therapeutics plc
21.46
+0.47%
CGEM Cullinan Therapeutics, Inc.
23.48
+1.34%
ANTX AN2 Therapeutics, Inc.
2.2399
-1.33%
ENGN enGene Holdings Inc.
13.01
+0.23%